Medico Remedies Limited (MEDICO) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Medico Remedies Limited ₹22.32, price ₹21.86, upside +2.1%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medico Remedies Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
52‑month range ₹17.11 – ₹96.70 · fair‑value band ₹10.75 – ₹29.01 · the ₹21.86 price screens below the ₹22.32 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Medico Remedies in your weekly email
Every Wednesday you see whether Medico Remedies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India.
Show more
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.
Stock analysis
Medico Remedies Limited (MEDICO) currently trades at ₹21.86, while our model-based Fair Value estimate is ₹22.32, so the stock looks roughly fairly valued today (gap 2.1%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹37.90 per share, and 11 of the 15 models we run sit above the ₹21.86 price.
Bear case: the Asset-Based group reads lowest at ₹6.09, and 4 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹10.75 (bear) to ₹29.01 (bull), the price of ₹21.86 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Medico Remedies Limited reported revenue of ₹2.1B in FY2026 versus ₹1.2B in FY2022, a compound +14.3%/yr. Reported net income was ₹131M in FY2026, compounding +28.5%/yr from FY2022.
Key figures
Market cap ₹3.4B (≈ $35.5M) · P/E ratio 13.8 · P/S ratio 0.88 · EPS (TTM) ₹1.58 · Net margin 6.4% · Return on equity 19.0% · Return on assets (EBIT) 13.0% · Operating margin 11.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 60% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 2%, MEDICO screens cheaper than that median.
Fair Value models
Bear ₹10.75Fair Value ₹22.32Bull ₹29.01
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.8008 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.56/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+36.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2021 (pandemic). Over 10 years: +12.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+29.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.38.3% vs 27.8%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 7%
2026 sits 58% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare Medico Remedies Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 585 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+2.1% · Above median
Profitability
Return on equity (TTM)19.0% · Top 25%
Return on assets6.4% · Top 25%
Net margin (TTM)6.4% · Below median
Operating margin (TTM)11.2% · Above median
Growth and dividend
Revenue growth37.5% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Medico Remedies Limited (MEDICO) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹22.32 versus a price of ₹21.86, about +2% upside (fairly valued).
What is the fair value of MEDICO?
Our model-based fair value for Medico Remedies Limited is ₹22.32 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹21.86.
What is the quality score of MEDICO?
Medico Remedies Limited has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medico Remedies Limited (MEDICO)?
Our model-based price target is the fair value of ₹22.32 (as of Sep 27, 2026) from 15 valuation models. Cautious scenario ₹10.75, optimistic scenario ₹29.01. It is a calculation from audited fundamentals, not an analyst target.
What is the Medico Remedies Limited stock forecast for 2026?
Our models put fair value at ₹22.32, about +2% upside versus a price of ₹21.86 (fairly valued). Cautious scenario ₹10.75, optimistic scenario ₹29.01. The calculation is refreshed regularly with new filings.
What is the revenue of Medico Remedies Limited (MEDICO)?
Medico Remedies Limited reported trailing-twelve-month revenue of about ₹2.1B (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Medico Remedies Limited (MEDICO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medico Remedies Limited it is ₹22.32 per share (as of Sep 27, 2026), against a price of ₹21.86. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Medico Remedies Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, MEDICO trades below its calculated fair value: price ₹21.86, fair value ₹22.32, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDICO?
No. The price is what the market pays today (₹21.86); the fair value is what the company's own numbers justify (₹22.32). For Medico Remedies Limited the two are ₹0.4600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medico Remedies Limited worth?
The market values Medico Remedies Limited at about ₹3.4B (market capitalisation, as of Sep 27, 2026). Per share that is ₹21.86; our models calculate a fair value of ₹22.32 per share.
What do the bullish and bearish scenarios say about MEDICO?
Our models span a range for Medico Remedies Limited: cautious scenario ₹10.75, base ₹22.32, optimistic ₹29.01 per share (as of Sep 27, 2026, price ₹21.86). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDICO?
Medico Remedies Limited trades at a price-to-earnings ratio of 13.8 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹22.32 is built from several models across several years. Other multiples: P/B 4.5, P/S 1.7, EV/EBITDA 20.0.
How solid is the balance sheet of Medico Remedies Limited (MEDICO)?
Balance-sheet figures for Medico Remedies Limited (as of Sep 27, 2026): return on equity 19.0%, debt of 0.00 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is MEDICO from its 52-week high?
Medico Remedies Limited trades at ₹21.86, about 60% below its 52-week high of ₹54.24 and 2% above the low of ₹21.53 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹22.32 is for.
Which stocks are comparable to Medico Remedies Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medico Remedies Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹21.86, calculated fair value ₹22.32 (+2%), Quality Score 51/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDICO calculated?
We run Medico Remedies Limited through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹22.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Medico Remedies Limited currently trades 2 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medico Remedies Limited (MEDICO)?
The closing price on Oct 1, 2026 was ₹21.86. Our model-based fair value is ₹22.32, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medico Remedies Limited right now?
The model range is unusually wide (₹10.75 to ₹29.01). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Medico Remedies Limited (MEDICO) come from?
Earnings per share at Medico Remedies Limited grew +27.5 % a year from 2015 to 2026. Broken into its drivers: revenue per share +12.6 %, EBIT margin +11.9 %, tax rate −0.4 %, residual (interest, one-offs) +1.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Medico Remedies Limited
How large is the market capitalisation of Medico Remedies Limited (MEDICO)?
The market capitalisation of Medico Remedies Limited is ₹3.4B (≈ $35.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medico Remedies Limited (MEDICO)?
The price-to-sales ratio of Medico Remedies Limited is 0.88 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medico Remedies Limited (MEDICO)?
Earnings per share at Medico Remedies Limited are ₹1.58 (price ÷ EPS = P/E 13.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medico Remedies Limited (MEDICO)?
The net margin of Medico Remedies Limited is 6.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medico Remedies Limited (MEDICO)?
The return on equity (ROE) of Medico Remedies Limited is 19.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medico Remedies Limited (MEDICO)?
On an EBIT basis the return on assets of Medico Remedies Limited is 13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medico Remedies Limited (MEDICO)?
The operating margin of Medico Remedies Limited is 11.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medico Remedies Limited (MEDICO)?
Revenue at Medico Remedies Limited is growing +37.5% versus a year earlier (3y avg +13.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medico Remedies Limited (MEDICO)?
Earnings per share at Medico Remedies Limited are growing +36.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Medico Remedies Limited (MEDICO) generate?
The free cash flow of Medico Remedies Limited is −₹34.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medico Remedies Limited (MEDICO) carry?
The net debt of Medico Remedies Limited is ₹173M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medico Remedies Limited in the live analysis
One click puts Medico Remedies Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
